文献速递结核与非结核分枝杆菌艾滋病与性传播感染

HIV感染女性受孕及孕早期暴露于3HP方案的安全性:WHIP3TB试验二次分析

Safety of Short-course Weekly Rifapentine and Isoniazid (3HP) for TB Preventive Treatment at Conception and During First Trimester in Women With HIV: A Secondary Analysis of the WHIP3TB trial.
PubMed 文献 · Clin Infect Dis · 2026-01-01

本研究为WHIP3TB试验的二次分析,评估HIV感染女性在受孕时或孕早期暴露于每周一次利福喷丁联合异烟肼(3HP)方案的安全性。222名参与者共发生236次妊娠,其中57次在用药期间受孕。暴露组与未暴露组的自然流产率和复合不良妊娠结局率相近,支持3HP在孕期使用的安全性。

要点

  • 孕早期暴露于3HP者自然流产率为12%(7/57),未暴露者为14%(22/162)。
  • 暴露组复合不良妊娠结局率为33%(19/57),未暴露组为35%(56/162)。
  • 结果支持HIV感染女性在受孕及孕早期使用3HP预防结核的安全性。

核心结论

  • HIV感染女性在受孕或孕早期暴露于3HP方案后,自然流产和复合不良妊娠结局与未暴露者相当,支持3HP在孕期使用的安全性。

研究设计与样本

  • 暴露定义为受孕时正在服用研究药物,未暴露定义为受孕发生在末次给药之后。
  • 复合不良妊娠结局包括死产、自然流产、低出生体重(<2500 g)、早产(<37周妊娠)或严重先天畸形。

主要发现

  • 236次妊娠中57次(24%)为暴露(3HP组51次,6个月异烟肼组6次),179次为未暴露。
  • 中位年龄32岁,中位抗逆转录病毒治疗时长2.9年(四分位距1.2-4.9年),中位CD4计数522 cells/L(四分位距345-684)。
  • 219次妊娠结局已知:活产162次(74%),流产51次(23%),死产6次(3%)。
  • 自然流产率暴露组12%(7/57)与未暴露组14%(22/162)相近。
  • 复合不良妊娠结局率暴露组33%(19/57)与未暴露组35%(56/162)相近。

临床怎么用

  • 对于接受抗逆转录病毒治疗的HIV感染女性,受孕及孕早期暴露于3HP方案未显示自然流产或复合不良妊娠结局风险增加,可为孕期结核预防用药决策提供安全性参考。

局限性

  • 本研究为试验的二次分析,暴露组样本量较小(57次妊娠),其中6个月异烟肼组仅6次妊娠。
  • 妊娠结局数据来自219次已知结局的妊娠,部分妊娠结局未获取。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The safety of a 3-month weekly rifapentine-isoniazid (3HP) for tuberculosis prevention in HIV-positive pregnant women on antiretroviral treatment is unknown. As part of the WHIP3TB trial, 3HP administered once or annually for 2 years was compared to 6 months of isoniazid. We report outcomes among women who became pregnant, with drug exposure in early pregnancy. METHODS: Women were classified as exposed if conception occurred while taking study drug, and unexposed if conception occurred after the last dose. Outcomes included live birth, stillbirth, or abortion. A composite adverse pregnancy outcome was defined as any of the following: stillbirth, spontaneous abortion, low birth weight (<2500 g), preterm delivery (<37 weeks' gestation), or major congenital anomalies. Outcomes were compared between exposed and unexposed groups. RESULTS: Among 2207 women aged 15-49 years enrolled between November 2016 and November 2017, 236 pregnancies occurred in 222 participants. Fifty-seven (24%) were exposed to study drug (51 in 3HP arm, 6 in 6 months of isoniazid arm) and 179 were unexposed. Median age was 32 years, median antiretroviral treatment duration 2.9 years (interquartile range; 1.2-4.9 years) and median CD4 count 522 cells/L; [interquartile range, 345-684). Of 219 pregnancies with known outcomes, 162 (74%) were live births, 51 (23%) abortions, and 6 (3%) stillbirths. Spontaneous abortions occurred at similar frequencies among exposed (12% [7/57]) and unexposed (14% [22/162]) groups with comparable rates of composite adverse outcomes (33% [19/57] vs 35% [56/162]). CONCLUSIONS: Spontaneous abortion and composite adverse pregnancy outcomes following first-trimester exposure to 3HP were comparable between exposed and unexposed groups, supporting the safety of 3HP in pregnancy.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Chihota V, Waggie Z, Cardenas V, et al. Safety of Short-course Weekly Rifapentine and Isoniazid (3HP) for TB Preventive Treatment at Conception and During First Trimester in Women With HIV: A Secondary Analysis of the WHIP3TB trial. Clin Infect Dis. 2026. PMID: 42142877. doi:10.1093/cid/ciag315

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。